研究業績

未来開拓センター HOME > 研究業績

業績

免疫細胞治療

  • Aoki T, Hino M, Koh K, Kyushiki M, Kishimoto H, Arakawa Y, Hanada R, Kawashima H, Kurihara J, Shimojo N, and Motohashi S. Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers. Pediatr. Blood Cancer 2016; 63(8):1461-4.
  • Hosokawa H, Tanaka T, Endo Y, Kato M, Shinoda K, Suzuki A, Motohashi S, Matsumoto M, Nakayama K I, and Nakayama T. Akt1-mediated Gata3 phosphorylation controls the repression of IFNγ in memory-type Th2 cells. Nat. Commun. 2016; 7:11289.
  • Mise N, Takami M, Suzuki A, Kamata T, Harada K, Hishiki T, Saito T, Terui K, Mitsunaga T, Nakata M, Ikeuchi T, Nakayama T, Yoshida H, and Motohashi S. Antibody-dependent cellular cytotoxicity toward neuroblastoma enhanced by activated invariant NKT cells. Cancer Sci. 2016; 107(3):233-241.
  • Horinaka A, Sakurai D, Ihara F, Makita Y, Kunii N, Motohashi S, Nakayama T, and Okamoto Y. Invariant NKT cells are resistant to circulating CD15+ myeloid-derived suppressor cells in patients with head and neck cancer. Cancer Sci. 2016; 107(3):207-216.
  • Hosokawa H, Kato M, Tohyama H, Tamaki Y, Endo Y, Kimura M Y., Tumes D J, Motohashi S, Matsumoto M, Nakayama K I, Tanaka T, and Nakayama T. Methylation of Gata3 at Arg261 regulates transactivation of the Il5 gene in T helper 2 cells. J. Biol. Chem. 2015; 290(21): 13095-13103.
  • Frigault M J, Lee J, Basil M, Carpenito C, Motohashi S, Scholler J, Kawalekar O U, Guedan S, McGettigan S, Posey A Jr, Ang S, Cooper L J, Platt J M, Johnson F B, Paulos C M, Zhao Y, Kalos M, Milone M C, and June C H. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol. Res. 2015; 3(4): 356-367.
  • Endo Y, Hirahara K, Iinuma T, Shinoda K, Tumes D J, Asou H K, Matsugae N, Obata-Ninomiya K, Yamamoto H, Motohashi S, Oboki K, Nakae S, Saito H, Okamoto Y, and Nakayama T. The Interleukin-33-p38 Kinase Axis Confers Memory T Helper 2 Cell Pathogenicity in the Airway. Immunity 2015; 42(2): 294-308.
  • Sun Y, Furihata T, Ishii S, Nagai M, Harada M, Shimozato O, Kamijo T, Motohashi S, Yoshino I, Kamiichi A, Kobayashi K, and Chiba K. Unique expression features of cancer-type organic anion transporting polypeptide 1B3 mRNA expression in human colon and lung cancers: potential biomarker implications. Clin. Transl. Med. 2014; 3: 37.
  • Watanabe Y, Onodera A, Kanai U, Ichikawa T, Obata-Ninomiya K, Wada T, Kiuchi M, Iwamura C, Tumes D J, Shinoda K, Yagi R, Motohashi S, Hirahara K, and Nakayama T. Trithorax complex component Menin controls differentiation and maintenance of T helper 17 cells. Proc. Natl. Acad. Sci. USA 2014; 111(35): 12829-12834.
  • Hamasaki S, Okamoto Y, Yonekura S, Okuma Y, Sakurai T, Iinuma T, Yamamoto H, Sakurai D, Horiguchi S, Yokota M.: Characteristics of the Chiba Environmental Challenge Chamber. Allergol Int.2014;63(1)41-50
  • Fujii S, Shimizu K, Okamoto Y, Kunii N, Nakayama T, Motohashi S, and Taniguchi M. NKT cells as an ideal anti-tumor immunotherapeutic. Front. Immunol. 2013;4:409
  • Hosokawa H, Tanaka T, Kato M, Shinoda K, Tohyama H, Hanazawa A, Tamaki Y, Hirahara K, Yagi R, Sakikawa I, Morita A, Nagira M, Poyurovsky, V. M, Suzuki Y, Motohashi S, and Nakayama T. Gata3/Ruvbl2 complex regulates T helper 2 cell proliferation via repression of Cdkn2c expression. Proc. Natl. Acad. Sci. USA. 2013;110(46):18626-18631.
  • Tumes D.J, Onodera A, Suzuki A, Shinoda K, Endo Y, Iwamura C, Hosokawa H, Koseki H, Tokoyoda K, Suzuki Y, Motohashi S, and Nakayama T. The polycomb protein Ezh2 regulates differentiation and plasticity of CD4+ T helper type-1 and type-2 cells. Immunity. 2013;39(5):819-832.
  • Okamoto Y, Ohta N, Okano M, Kamijo A, Gotoh M, Suzuki M, Takeno S, Terada T, Hanazawa T, Horiguchi S, Honda K, Matsune S, Yamada T, Yuta A, Nakayama T, Fujieda S. Guiding principles of subcutaneous immunotherapy for allergic rhinitis in Japan. Auris Nasus Larynx.2013;41:1-5.
  • Yonekura S, Okamoto Y, Yamamoto H, Sakurai T, Iinuma T, Sakurai D, Hanazawa T:Randomized double-blind study of prophylactic treatment with an antihistamine for seasonal allergic rhinitis. Int Arch Allergy Immunol 2013;162:71-8
  • Higaki T, Okano M, Kariya S, Fujiwara T, Haruna T, Hirai H, Murai A, Gotoh M, Okubo K, Yonekura S, Okamoto Y, Nishizaki K.:Determining minimal clinically important differences in Japanese cedar/cypress pollinosis patients.Allergol Int. 2013;62:487-93
  • Kinoshita T, Nohata N, Hanazawa T, Kikkawa N, Yamamoto N, Yoshino H, Itesako T, Enokida H, Nakagawa M, Okamoto Y, Seki N. Tumour-suppressive microRNA-29s inhibit cancer cell migration and invasion by targeting laminin-integrin signalling in head and neck squamous cell carcinoma. Br J Cancer. 2013 ;109:2636-45
  • Nohata N, Hanazawa T, Kinoshita T, Inamine A, Kikkawa N, Itesako T, Yoshino H, Enokida H, Nakagawa M, Okamoto Y, Seki N. Tumour-suppressive microRNA-874 contributes to cell proliferation through targeting of histone deacetylase 1 in head and neck squamous cell carcinoma. Br J Cancer. 2013 ;108:1648-58.
  • Kunii N, Zhao Y, Jiang S, Liu X, Scholler J, Balagopalan L, Samelson LE, Milone MC, and June CH. Enhanced function of redirected human T cells expressing linker for activation of T cells that is resistant to ubiquitylation. Hum Gene Ther. 2013 24(1):27-37
  • Nagato K, Motohashi S, Ishibashi F, Okita K, Yamasaki K, Moriya Y, Hoshino H, Yoshida S, Hanaoka H, Fuji S, Taniguchi M, Yoshino I, and Nakayama T. Accumulation of activated invariant natural killer T cells in the tumor microenvironment after α-Galactosylceramide-pulsed antigen presenting cells. J Clin.Immunol. 2012; 32: 1071-1081.
  • Iwamura C, Shinoda K, Endo Y, Watanabe Y, Tumes D.J, Motohashi S, Kawahara K, Kinjo Y, Nakayama T. Regulation of memory CD4 T-cell pool size and function by natural killer T cells in vivo. Proc Natl Acad Sci U S A. 2012; 109(42): 16992-16997
  • Kuwahara M, Yamashita M, Shinoda K, Tofukuji S, Onodera A, Shinnakasu R, Motohashi S, Hosokawa H, Tumes D, Iwamura C, Lefebvre V, and Nakayama T. The transcription factor Sox4 is a downstream target of TGF-β signaling and suppresses GATA3-induced TH2 cell differentiation. Nat. Immunol. 2012; 13(8): 778-786
  • Nagai M, Furihata T, Matsumoto S, Ishii S, Motohashi S, Yoshino I, Ugajin M, Miyajima A, Matsumoto S, and Chiba K. Identification of a new organic anion transporting polypeptide 1B3 mRNA isoform primarily expressed in human cancerous tissues and cells. Biochem Biophys Res Commun. 2012; 418(4): 818-823
  • Yamashita J, Iwamura C, Mitsumori K, Hosokawa H, Sasaki T, Takahashi M, Tanaka H, Kaneko K, Hanazawa A, Watanabe Y, Shinoda K, Tumes D, Motohashi S, Nakayama T. Murine Schnurri-2 controls Natural Killer cell function and lymphoma development. Leuk. Lymphoma. 2012; 53(3): 479-486
  • Kitajima M, Ito T, Tumes DJ, Endo Y, Onodera A, Hashimoto K, Motohashi S, Yamashita M, Nishimura T, Ziegler SF, Nakayama T. Memory type 2 helper T cells induce long-lasting antitumor immunity by activating natural killer cells. Cancer Res. 2011; 71(14): 4790-4798.
  • Motohashi S, Okamoto Y, and Nakayama T. Clinical trials of invariant Natural Killer T cell-based immunotherapy for cancer. In the book "Natural killer T cells. : setting the balance in the regulation of tumor immunity". Edited by Berzofsky and Terabe. 2011; 185-198.
  • Kurosaki M, Horiguchi S, Yamasaki K, Uchida Y, Motohashi S, Nakayama T, Sugimoto A, and Okamoto Y. Migration and immunological reaction after the administration of αGalCer-pulsed antigen-presenting cells into the submucosa of patients with head and neck cancer. Cancer Immunol. Immunother. 2011; 60(2): 207-215.
  • Motohashi S, Okamoto Y, Yoshino I, and Nakayama T. Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer. Clin Immunol. 2011; 140(2):167-176.
  • Yamasaki K, Horiguchi S, Kurosaki M, Kunii N, Nagato K, Hanaoka H, Shimizu N, Ueno N, Yamamoto S, Taniguchi M, Motohashi S, Nakayama T, and Okamoto Y. Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy. Clin. Immunol. 2011; 138(3): 255-265.
  • Okita K, Motohashi S, Shinnakasu R, Nagato K, Yamasaki K, Sato Y, Kitamura H, Hijikata A, Yamashita M, Shimizu K, Fujii S, Ohara O, Taniguchi M, Sakaida I, and Nakayama T. A set of genes associated with the interferon-γ response of lung cancer patients undergoing α-galactosylceramide-pulsed dendritic cell therapy. Cancer Sci. 2010; 101 (11): 2333-2340.
  • Ishii Y, Motohashi S, Shimizu K, Nakayama T, Taniguchi M, and Fujii S. Application of NKT cells in immunotherapy. Curr Immunol Rev. 2010; 6: 109-115.
  • Fujii S, Motohashi S, Shimizu K, Nakayama T, Yoshiga Y, and Taniguchi M. Adjuvant activity mediated by iNKT cells. Semin Immunol. 2010; 22 (2): 97-102.
  • Suzuki M, Wada H, Yoshino M, Tian L, Shigematsu H, Suzuki H, Alaa M, Tamura H, Fujiwara T, Nagato K, Motohashi S, Moriya Y, Hoshino H, Yoshida S, Shibuya K, Hiroshima K, Nakatani Y, and Yoshino I. Molecular Characterization of Chronic Obstructive Pulmonary Disease-Related Non-Small Cell Lung Cancer Through Aberrant Methylation and Alterations of EGFR Signaling. Ann Surg Oncol. 2010; 17 (3): 878-888.
  • Alaa M, Suzuki M, Yoshino M, Tian L, Suzuki H, Nagato K, Fujiwara T, Wada H, Moriya Y, Hoshino H, Motohashi S, Yoshida S, Shibuya K, Hiroshima K, Nakatani Y. Abdrabou A, Elkholy M, Mahfouz T, and Yoshino I. Prostaglandin E2 receptor 2 overexpression in squamous cell carcinoma of the lung correlates with p16INK4A methylation and an unfavorable prognosis. Int J Oncol. 2009; 34 (3): 805-812.
  • Kitajima M, Iwamura C, Miki H T, Shinoda K, Endo Y, Watanabe Y, Shinnakasu R, Hosokawa H, Hashimoto K, Motohashi S, Koseki H, Ohara O, Yamashita M, and Nakayama T. Enhanced Th2 cell differentiation and allergen-induced airway inflammation in Zfp35-deficient mice. J Immunol. 2009; 183 (8): 5388-5396.
  • Kunii N, Horiguchi S, Motohashi S, Yamamoto H, Ueno N, Yamamoto S, Sakurai D, Taniguchi M, Nakayama T, and Okamoto Y. Combination therapy of in vitro-expanded natural killer T cells and α-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma. Cancer Sci. 2009; 100 (6): 1092-1098.
  • Miki H T, Hasegawa A, Iwamura C, Shinoda K, Tofukuji S, Watanabe Y, Hosokawa H, Motohashi S, Hashimoto K, Shirai M, Yamashita M, and Nakayama T. CD69 controls the pathogenesis of allergic airway inflammation. J Immunol. 2009; 183 (12): 8203-8215.
  • Motohashi S, Nagato K, Kunii N, Yamamoto H, Yamasaki K, Okita K, Hanaoka H, Shimizu N, Suzuki M, Yoshino I, Taniguchi M, Fujisawa T, and Nakayama T. A phase I-II study of α-Galactosylceramide(KRN7000)-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol. 2009; 182 (4): 2492-2501.
  • Motohashi S, and Nakayama T. Invariant natural killer T cell-based immunotherapy for cancer. Immunotherapy. 2009; 1 (1): 73-82.
  • Motohashi S, and Nakayama T. Natural killer T cell-mediated immunotherapy for malignant diseases. Frontiers in Bioscience. 2009; 1(1): 108-116.
  • Ito T, Hasegawa A, Hosokawa H, Yamashita M, Motohashi S, Naka T, Okamoto Y, Fujita Y, Ishii Y, Taniguchi M, Yano I, and Nakayama T. Human Th1 differentiation induced by lipoarabinomannan / lipomannon from Mycobacterium bovis BCG Tokyo-172. International Immunology. 2008; 20 (7): 849-860.
  • Shinnakasu R, Yamashita M, Kuwahara M, Hosokawa H, Hasegawa A, Motohashi S, and Nakayama T. Gfi1-mediated stabilization of GATA3 protein is required for Th2 cell differentiation. J Biol Chem. 2008; 283(42): 28216-28225.
  • Suzuki M, Mohamed S, Nakajima T, Kubo R, Tian L, Fujiwara T, Suzuki H, Nagato K, Chiyo M, Motohashi S, Yasufuku K, Iyoda A, Yoshida S, Sekine Y, Shibuya K, Hiroshima K, Nakatani Y, Yoshino I, and Fujisawa T. Aberrant methylation of CXCL12 in non-small cell lung cancer is associated with an unfavorable prognosis. Int J Oncol. 2008; 33 (1): 113-119.
  • Yamashita M, Kuwahara M, Suzuki A, Hirahara K, Shinnakasu R, Hosokawa H, Hasegawa A, Motohashi S, Iwama A, and Nakayama T. Bmi1 regulates memory CD4 T cell survival via repression of the Noxa gene. J Exp Med. 2008; 205 (5): 1109-1120.

ページの先頭へ

酵素補充療法

  • Tanino A, Okura T, Nagao T, Kukida M, Enomoto D, Miyoshi K, Higaki J, Kuroda M, Bujo H. (2016) A case of acquired lecithin:cholesterol acyltransferase deficiency with sarcoidosis that remitted spontaneously. CEN Case Rep. 5, 1-5.
  • 黒田正幸、武城英明、齋藤康、横手幸太郎. 遺伝的酵素欠損症に対する遺伝子・細胞治療. 内分泌疾患のtrends & topics 2016. 月刊Mebio. メジカルレビュー社、2016.33.75-82.
  • 黒田正幸、横手幸太郎. 遺伝子導入脂肪細胞の移植による持続的酵素補充療法-家族性LCAT 欠損症を対象とした治療法開発と難治性疾患への応用展開-,再生医療等製品の開発と実用化展望 第16章; p123-130、シーエムシー出版、2016年6月発行
  • 黒田正幸、武城英明、麻生雅是、齋藤康、横手幸太郎. 疾患治療用タンパク質分泌加工脂肪細胞の創薬開発と難病治療. 薬学雑誌-Symposium Review- 2016, 136; 705-709.
  • Kosaka K, Kubota Y, Adachi N, Akita S, Sasahara Y, Kira T, Kuroda M, Mitsukawa N, Bujo H, and Satoh K. (2016) Human adipocytes from the subcutaneous superficial layer have greater adipogenic potential and lower PPAR-γ DNA methylation levels than deep layer adipocytes. Am. J. Physiol. Cell Physiol. 311, C322-329.
  • Adachi N, Kubota Y, Kosaka K, Akita S, Sasahara Y, Kira T, Kuroda M, Mitsukawa N, Bujo H, Satoh K. (2015) Low-dose radiation pretreatment improves survival of human ceiling culture-derived proliferative adipocytes (ccdPAs) under hypoxia via HIF-1 alpha and MMP-2 induction. Biochem Biophys Res Commun. 463, 1176-1183.
  • Fujisaki K, Fujimoto H, Sangai T, Nagashima T, Sakakibara M, Shiina N, Kuroda M, Aoyagi Y, Miyazaki M. (2015) Cancer-mediated adipose reversion promotes cancer cell migration via IL-6 and MCP-1. Breast Cancer Res Treat. 150: 255-263
  • 瀬川茉莉、星 明彦、成瀬紘也、黒田正幸、武城英明、宇川義一. (2015) Valosin-containing protein (VCP) 遺伝子変異を認めた家族性筋萎縮性側索硬化症の1例 臨床神経学. 55, 914-920.
  • 黒田正幸、横手幸太郎. リポ蛋白受容体, 高LDL-C血症・低HDL-C血症-診断と治療のABC 101-、最新医学別冊、最新医学社、2015/1/15発行
  • 黒田正幸、武城英明. 脂質異常症の遺伝子細胞治療−LCAT欠損症患者への新規治療法の開発−, Annual Review 2015 糖尿病・代謝・内分泌、中外医学社、2015, 128-132
  • 黒田正幸、武城英明. LCAT欠損症の診断と治療, 腎と透析(特集、腎のたまり病)、東京医学社、2014, 77; 226-230.
  • Kuroda M, Holleboom AG, Stroes E, Asada S, Aoyagi Y, Kamata K, Yamashita S, Ishibashi S, Saito Y, Bujo H. Lipoprotein subfractions highly associated with renal damage in familial LCAT deficiency Arterioscler Thromb Vasc Biol. 2014; 34(8), 1756-1762.
  • Naito S, Kamata M, Furuya M, Hayashi M, Kuroda M, Bujo H, Kamata K. Amelioration of circulating lipoprotein profile and proteinuria in a patient with LCAT deficiency due to a novel mutation (Cys74Tyr) in the lid region of LCAT under a fat-restricted diet and ARB treatment. Atherosclerosis. 2013; 228, 193-197.
  • Ogita M, Miyauchi K, Dohi T, Tsuboi S, Miyazaki T, Yokoyama T, Yokoyama K, Shimada K, Kurata T, Jiang M, Bujo H, Daida H. Increased circulating soluble LR11 in patients with acute coronary syndrome. Clin Chim Acta. 2013; 415: 191-194.
  • Fukaya Y, Kuroda M, Aoyagi Y, Asada S, Kubota Y, Okamoto Y, Nakayama T, Saito Y, Satoh K, and Bujo H. Platelet-rich plasma inhibits the apoptosis of highly adipogenic homogeneous preadipocytes in an in vitro culture system. Exp Mol Med. 2012; 44: 330-339.
  • Takahashi M, Bujo H, Shiba T, Jiang M, Maeno T, Shirai K. Enhanced circulating soluble LR11 in patients with diabetic retinopathy. Am J Ophthalmol. 2012; 154: 187-192.
  • Sakai S, Nakaseko C, Takeuchi M, Ohwada C, Shimizu N, Tsukamoto S, Kawaguchi T, Jiang M, Sato Y, Ebinuma H, Yokote K, Iwama A, Fukamachi I, Schneider WJ, Saito Y, and Bujo H. Circulating soluble LR11/SorLA levels are highly increased and ameliorated by chemotherapy in acute leukemias. Clin Chim Acta. 2012; 413: 1542-1548.
  • Harada-Shiba M, Arai H, Okamura T, Yokote K, Oikawa S, Nohara A, Okada T, Ohta T, Bujo H, Watanabe M, Wakatsuki A, Yamashita S. Multicenter study to determine the diagnosis criteria of heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb. 2012; 19: 1019-1026.
  • Harada-Shiba M, Arai H, Oikawa S, Ohta T, Okada T, Okamura T, Nohara A, Bujo H, Yokote K, Wakatsuki A, Ishibashi S, Yamashita S. Guidelines for the management of familial hypercholesterolemia. J Atheroscler Thromb. 2012; 19: 1043-1060.
  • Fukaya Y, Kuroda M, Aoyagi Y, Asada S, Kubota Y, Okamoto Y, Nakayama T, Saito Y, Satoh K, Bujo H. Platelet-rich plasma inhibits the apoptosis of highly adipogenic homogeneous preadipocytes in an in vitro culture system. Exp Mol Med. 2012; 44(5): 330-339
  • Aoyagi Y, Kuroda M, Asada S, Tanaka S, Konno S, Tanio M, Aso M, Okamoto Y, Nakayama T, Saito Y, Bujo H. Fibrin glue is a candidate scaffold for long-term therapeutic protein expression in spontaneously differentiated adipocytes in vitro. Exp Cell Res. 2012; 318(1): 8-15.
  • Katayama A, Wada J, Usui-Kataoka H, Yamasaki H, Teshigawara S, Terami T, Inoue K, Kanzaki M, Murakami K, Nakatsuka A, Sugiyama H, Koide N, Bujo H, Makino H. Two novel mutations of lecithin:cholesterol acyltransferase (LCAT) gene and the influence of APOE genotypes on clinical manifestations. NDT Plus. 2011;4:299-302
  • Kuroda M, Bujo H, Aso M, and Saito Y. Adipocytes as a vehicle for ex vivo gene therapy: Novel replacement therapy for diabetes and other metabolic diseases. J Diabetes Invest. 2011; 2: 333-340.
  • Aoyagi Y, Kuroda M, Asada S, Bujo H, Tanaka S, Konno S, Tanio M, Ishii I, Aso M, and Saito Y. Fibrin glue increases the cell survival and the transduced gene product secretion of the ceiling culture-derived adipocytes transplanted in mice. Exp Mol Med. 2011; 43: 161-7.
  • Asada S, Kuroda M, Aoyagi Y, Fukaya Y, Tanaka S, Konno S, Tanio M, Aso M, Okamoto Y, Nakayama T, Saito Y, and Bujo H. Ceiling culture-derived proliferative adipocytes retain high adipogenic potential suitable for use as a vehicle for gene transduction therapy. Am J Physiol Cell Physiol. 2011; 301: C181-C185.
  • Asada S, Kuroda M, Aoyagi Y, Bujo H, Tanaka S, Konno S, Tanio M, Ishii I, Aso M, and Saito Y. Disturbed apolipoprotein A-I-containing lipoproteins in fish-eye disease are improved by the lecithin:cholesterol acyltransferase produced by gene-transduced adipocytes in vitro. Mol Genet Metab. 2011; 102: 229-31.
  • Kuroda M, Aoyagi Y, Asada S, Bujo H, Tanaka S, Konno S, Tanio M, Ishii I, Machida K, Matsumoto F, Satoh K, Aso M, Saito Y. Ceiling culture-derived proliferative adipocytes are a possible delivery vehicle for enzyme replacement therapy in lecithin:cholesterol acyltransferase deficiency. The Open Gene Ther J. 2011; 4: 1-10.
  • Nakata Z, Nagae M, Yasui N, Bujo H, Nogi T, and Takagi J. Crystallization and preliminary crystallographic analysis of human LR11 Vps10p domain. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011; 67(Pt 1): 129-32.
  • Ikeuchi T, Hirayama S, Miida T, Fukamachi I, Tokutake T, Ebinuma H, Takubo K, Kaneko H, Kasuga K, Kakita A, Takahashi H, Bujo H, Saito Y, Nishizawa M. Increased Levels of Soluble LR11 in Cerebrospinal Fluid of Alzheimer Disease. Demen Geriat Cognit Disord. 2010; 30 :28-32.
  • Takahashi M, Bujo H, Jiang M, Noike H, Saito Y, Shirai K. Enhanced circulating soluble LR11 in patients with coronary organic stenosis. Atherosclerosis. 2010; 210: 581-4.
  • Unoki-Kubota H, Yamagishi SI, Takeuchi M, Bujo H, Saito Y. Pyridoxamine, an Inhibitor of Advanced Glycation End Product (AGE) Formation Ameliorates Insulin Resistance in Obese, Type 2 Diabetic Mice. Protein Pept Lett. 2010; 17: 1177-81.
  • Unoki-Kubota H, Yamagishi S, Takeuchi M, Bujo H, Saito Y. Pyridoxamine, an inhibitor of advanced glycation end product (AGE) formation ameliorates insulin resistance in obese, type 2 diabetic mice. Protein Pept Lett. 2010; 17: 1177-81.
  • Matsuo M, Ebinuma H, Fukamachi I, Jiang M, Bujo H, Saito Y. Development of an Immunoassay for the Quantification of Soluble LR11, a Circulating Marker of Atherosclerosis. Clin Chem. 2009; 55: 1801-8.
  • Neff Y, Bujo H, Miyashita Y, Uchida D, Ban T, Tashiro T, Yamazaki K, Ishikawa K, Tokuyama T, Jiang M, Kawamura T, Saito, Y. The potential role of patient awareness regarding one's own medical data in the management of lifestyle-related. Chiba Medical Journal. 2009; 85: 125-34.
  • Tashiro J, Miyazaki O, Nakamura Y, Miyazaki A, Fukamachi I, Bujo H, and Saito Y. Plasma Preβ1-HDL level is elevated in unstable angina pectoris. Atherosclerosis. 2009; 204: 595-600.
  • Jiang M, Bujo H, Ohwaki K, Unoki H, Yamazaki H, Kanaki T, Shibasaki M, Azuma K, Harigaya K, Schnerider W J, Saito Y. AngII - stimulated migration of vascular SMC is dependent on LR11. J Clin Invest. 2008; 118: 2733-46.
  • Kawamura T, Murakami K, Bujo H, Unoki H, Jiang M, Nakayama T, Saito Y. Matrix metalloproteinase-3 enhances the free fatty acids-induced VEGF expression in adipocytes through toll-like receptor 2. Exp Biol Med. 2008; 283: 1213-21.
  • Kuramochi D, Unoki H, Bujo H, Kubota Y, Jiang M, Rikihisa N, Udagawa A, Yoshimoto S, Ichinose M, Saito Y. Matrix metalloproteinase 2 improves the transplanted adipocyte survival in mice. Eur J Clin Invest. 2008; 38: 752-9.
  • Yamashita S, Bujo H, Arai H, Harada-Shiba M, Matsui S, Fukushima M, Saito Y, Kita T, Matsuzawa, Y. Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb. 2008; 15: 292-303.

ページの先頭へ

血管新生治療

  • Nakagomi A, Okada S, Shoji T, Kobayashi Y. Crucial Effect of Calibration Methods on the Association Between Central Pulsatile Indices and Coronary Atherosclerosis. Am J Hypertens. in press
  • Saito Y, Okada S, Funabashi N, Kobayashi Y. ANCA-negative eosinophilic granulomatosis with polyangitis (EGPA) manifesting as a large intracardiac thrombus and glomerulonephritis with angionecrosis. BMJ Case Rep. in press
  • Nakagomi A, Okada S, Shoji T, Kobayashi Y. Aortic pulsatility assessed by an oscillometric method is associated with coronary atherosclerosis in elderly people. Blood Press. 2016 May 4:1-8.
  • Shimizu I, Yoshida Y, Katsuno T, Minamino T. Adipose tissue inflammation in diabetes and heart failure Microbes and Infection. 2013; 15(1): 11-17
  • Okada S, Yokoyama M, Toko H, Tateno K, Moriya J, Shimizu I, Nojima A, Ito T, Yoshida Y, Kobayashi Y, Katagiri H, Minamino T and Komuro I. Brain-Deriverd Neurotrophic Factor protects against cardiac dysfunction after myocardial infarction via a central nervous system-mediated pathway. Arterioscler Thromb Vasc Biol. 2012; 32(8): 1902-1909
  • Naito AT, Sumida T, Nomura S, Liu ML, Higo T, Nakagawa A, Okada K, Sakai T, Hashimoto A, Hara Y, Shimizu I, Zhu W, Toko H, Katada A, Akazawa H, Oka T, Lee JK, Minamino T, Nagai T, Walsh K, Kikuchi A, Matsumoto M, Botto M, Shiojima I, Komuro I. Complement C1q Activates Canonical Wnt Signaling and Promotes Aging-Related Phenotypes. Cell. 2012; 149(6): 1298-1313
  • Shimizu I, Yoshida Y, Katsuno T, Tateno K, Okada S, Moriya J, Yokoyama M, Nojima A, Ito T, Zechner R, Komuro I, Kobayashi Y, Minamino T. p53-induced adipose tissue inflammation is critically involved in the development of insulin resistance in heart failure. Cell Metab. 2012; 15: 51-64.
  • Nakano D, Lei B, Kitada K, Hitomi H, Kobori H, Mori H, Deguchi K, Masaki T, Minamino T, Nishiyama A. Aldosterone Does Not Contribute to Renal p21 Expression During the Development of Angiotensin II-Induced Hypertension in Mice. Am J Hypertens. in press.
  • Odaka K, Aoki I, Moriya J, Tateno K, Tadokoro H, Kershaw J, Minamino T, Irie T, Fukumura T, Komuro I, and Saga T. In vivo tracking of transplanted mononuclear cells using manganese-enhanced magnetic resonance imaging. PLoS One. 2011; 6: e25487.
  • Xiaojing Wu, Yunzeng Zou, Qi Zhou, Lan Huang, Hui Gong, Aijun Sun, Kaoru Tateno, Ken-ichi Katsube, Freddy Radtke, Junbo Ge, Tohru Minamino, Issei Komuro. Role of Jagged1 in Arterial Lesions After Vascular Injury. Arterioscler Thromb Vasc Biol. 2011.
  • Naito AT, Okada S, Minamino T, Iwanaga K, Liu M, Sumida T, Nomura S, Sahara N, Mizoroki T, Takashima A, Akazawa H, Nagai T, Shiojima I, Komuro I. Promotion of CHIP-mediated p53 degradation protects the heart from ischemic injury. Circ Res. 2010; 106 :1692-1702.
  • Minamino T. Role of cellular senescence in lifestyle-related disease. Circ J. 2010; 74: 2527-2533.
  • Moriya J, Minamino T, Tateno K, Okada S, Uemura A, Shimizu I, Yokoyama M, Nojima A, Okada M, Koga H, Komuro I. Inhibition of semaphorin as a novel strategy for therapeutic angiogenesis. Circ Res. 2010; 106: 391-398.
  • Toko H, Takahashi H, Kayama Y, Oka T, Minamino T, Okada S, Morimoto S, Zhan DY, Terasaki F, Anderson ME, Inoue M, Yao A, Nagai R, Kitaura Y, Sasaguri T, Komuro I. Ca2+/calmodulin-dependent kinase IIdelta causes heart failure by accumulation of p53 in dilated cardiomyopathy. Circulation. 2010; 122: 891-899.
  • Toko H, Takahashi H, Kayama Y, Okada S, Minamino T, Terasaki F, Kitaura Y, and Komuro I. ATF6 is important under both pathological and physiological states in the heart. J Mol Cell Cardiol. 2010; 49:113-20.
  • Shimizu I, Minamino T, Toko H, Okada S, Ikeda H, Yasuda N, Tateno K, Moriya J, Yokoyama M, Nojima A, Koh GY, Akazawa H, Shiojima I, Kahn CR, Abel ED and Komuro I. Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload. J Clin Invest. 2010; 120: 1506-1514.
  • Kayama Y, Minamino T, Toko H, Sakamoto M, Shimizu I, Takahashi H, Okada S, Tateno K, Moriya J, Yokoyama M, Nojima A, Yoshimura M, Egashira K, Aburatani H and Komuro I. Cardiac 12/15-lipoxygenase-induced inflammation is involved in heart failure. J Exp Med. 2009; 206: 1565-1574.
  • Minamino T, Orimo M, Shimizu I, Kunieda T, Yokoyama M, Ito T, Nojima A, Nabetani A, Oike Y, Matsubara H, Ishikawa F, Komuro I. A crucial role for adipose tissue p53 in the regulation of insulin resistance. Nat Med. 2009; 15: 1082-1087.
  • Minamino, T. Gap junctions mediate the spread of ischemia-reperfusion injury. Circ J. 2009; 73, 1591-1592.
  • Moriya J, Minamino T, Tateno K, Shimizu N, Kuwabara Y, Sato Y, Saito Y and Komuro I. Long-term outcome of therapeutic neovascularization using peripheral blood mononuclear cells for limb ischemia. Circ Cardiovasc Intervent. 2009; 2: 245-254.
  • Orimo M, Minamino T, Miyauchi H, Tateno K, Okada S, Moriya J, Komuro I. Protective role of SIRT1 in diabetic vascular dysfunction. Arterioscler Thromb Vasc Biol. 2009; 29: 889-894.
  • Kunieda T, Minamino T, Miura K, Katsuno T, Tateno K, Miyauchi H, Kaneko S, Bradfield CA, FitzGerald GA, Komuro I. Reduced nitric oxide causes age-associated impairment of circadian rhythmicity. Circ Res. 2008; 102: 607-614.
  • Minamino T and Komuro I. Vascular aging: insights from studies on cellular senescence, stem cell aging, and progeroid syndromes. Nat Clin Pract Cardiovasc Med. 2008; 5: 637-648.
  • Minamino T and Komuro I. Role of telomeres in vascular senescence. Front Biosci. 2008; 13: 2971-2979.
  • Nishi J, Minamino T, Miyauchi H, Nojima A, Tateno K, Okada S, Orimo M, Moriya J, Fong GH, Sunagawa K, Shibuya M, Komuro I. Vascular Endothelial Growth Factor Receptor-1 Regulates Postnatal Angiogenesis Through Inhibition of the Excessive Activation of Akt. Circ Res. 2008; 103: 261-268.
  • Toko H, Minamino T, Komuro I. Role of heat shock transcriptional factor 1 and heat shock proteins in cardiac hypertrophy. Trends Cardiovasc Med. 2008; 18: 88-93.
  • Tateno K, Minamino T, Moriya J, Katada A, Yokoyama M, Miura K, Komuro I. Cell Therapy for Cardiovascular Diseases. Ann Vasc Dis. 2008; 1: 66-79.
  • Zhu W, Shiojima I, Ito Y, Li Z, Ikeda H, Yoshida M, Naito AT, Nishi J, Ueno H, Umezawa A, Minamino T, Nagai T, Kikuchi A, Asashima M and Komuro I. IGFBP-4 is an inhibitor of canonical Wnt signaling required for cardiogenesis. Nature. 2008; 454: 345-349.

ページの先頭へ

臨床試験部

  • Kobayashi K, Yokoh H, Sato Y, Takemoto M, Uchida D, Kanatsuka A, Kuribayashi N, Terano T, Hashimoto N, Sakurai K, Hanaoka H, Ishikawa K, Onishi S, Yokote K. SUCCESS Study Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-inferiority trial. Diabetes Obes Metab. 16(8):761-5. 2014 Aug.
  • Katayama K, Misawa S, Sato Y, Sobue G, Yabe I, Watanabe O, Nishizawa M, Kusunoki A, Kikuchi S, Nakashima I, Ikeda S, Kohara N, Kanda T, Kira J, Hanaoka H, Kuwabara S.Japanese POEMS syndrome with Thalidomide(J-POST) Trial: study protocol for a phase U/V multicentre, randomised, double-blind, placebo-controlled trial. BMJ Open. 5 (1):e007330. 2015 Jan 8.
  • Yokoh H, Kobayashi K, Sato Y, Takemoto M, Uchida D, Kanatsuka A, uribayashi N, Terano T, Hashimoto N, Sakurai K, Hanaoka H, Ishikawa K, Onishi S, Yokote K. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with lpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin-1): A multicenter, randomized, open-label, non-inferiority trial. J Diabetes Investig. 6(2):182-91. 2015 Mar.
  • Katsuno M, Banno H. Japan SBMA Interventional Trial for TAP-144-SR (JASMITT) study group. Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010; 875-84.
  • Hanaoka H, Oishi Y, Sakamoto A. Selective Reduction and Recovery of Invariant Vα24JαQ TCR T Cells in Correlation with Disease Activity in Patients with Chronic Graft-versus-Diseases. Chiba Medical Journal. 2009; 85: 113-124.
  • Motohashi S, Nagato K, Kunii N, Yamamoto H, Yamasaki K, Okita K, Hanaoka H, Shimizu N, Suzuki M, Yoshino I, Taniguchi M, Fujisawa T, Nakayama T. A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol. 2009; 15: 182(4): 2492-501.
  • Yokote K, Saito Y. Influence of statins on glucose tolerance in patients with type 2 diabetes mellitus: subanalysis of the collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). J Atheroscler Thromb. 2009; 297-8.
  • 千葉大学医学部 附属病院 臨床試験部
  • 千葉大学グローバルCOEプログラム 免疫システム統御治療学の国際教育研究拠点
  • かずさDNA研究所
  • 千葉大学医学部
  • 理化学研究所免疫アレルギー科学総合研究センター
  • 放射線医学総合研究所
  • [医療関係者の方へ]先進医療のお知らせ(NKT細胞免疫治療)
  • [肺癌患者さんへ]先進医療のお知らせ(NKT細胞免疫治療)
  • HDL-コレステロール値が低いと診断された方へ
  • 家族性LCAT欠損症の治療法

PAGE TOP